1-ethyl-2-benzimidazolinone has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bavencoffe, A; Bidaux, G; Bonnal, JL; Delcourt, P; Dewailly, E; Fleurisse, L; Gackière, F; Gosset, P; Lallet-Daher, H; Mariot, P; Mauroy, B; Prevarskaya, N; Roudbaraki, M; Skryma, R; Slomianny, C; Urbain, R | 1 |
| Coghlan, MJ; Gopalakrishnan, M; Parihar, AS; Shieh, CC | 1 |
2 other study(ies) available for 1-ethyl-2-benzimidazolinone and Prostatic Neoplasms
| Article | Year |
|---|---|
Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.
Topics: Benzimidazoles; Calcium; Calcium Channels; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; G1 Phase; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Intracellular Signaling Peptides and Proteins; Male; Membrane Potentials; Prostatic Neoplasms; RNA, Messenger; S100 Proteins; TRPV Cation Channels; Tumor Suppressor Protein p53 | 2009 |
Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation.
Topics: Benzimidazoles; Calcium Channel Agonists; Calcium Channel Blockers; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Potassium Channels, Calcium-Activated; Prostatic Neoplasms; Riluzole | 2003 |